IRLAB Therapeutics AB (publ) (IRLAB-A.ST)
SEK 11.25
(0.0%)
SEK 11.25
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 27.56 Million SEK | 593.31% |
| 2022 | 3.97 Million SEK | -39.76% |
| 2021 | 6.6 Million SEK | 125.49% |
| 2020 | 2.92 Million SEK | -35.57% |
| 2019 | 4.54 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | -100.0% |
| 2016 | 400 Thousand SEK | 0.0% |
| 2015 | 400 Thousand SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 27.6 Million SEK | 0.15% |
| 2024 Q2 | 52.63 Million SEK | 90.65% |
| 2024 Q3 | 55.9 Million SEK | 14.54% |
| 2023 Q3 | 1.29 Million SEK | -41.14% |
| 2023 Q2 | 2.2 Million SEK | -28.87% |
| 2023 Q4 | 27.56 Million SEK | 2028.65% |
| 2023 Q1 | 3.09 Million SEK | -22.21% |
| 2023 FY | 27.56 Million SEK | 593.31% |
| 2022 Q1 | 5.85 Million SEK | -11.27% |
| 2022 Q3 | 4.33 Million SEK | -14.95% |
| 2022 FY | 3.97 Million SEK | -39.76% |
| 2022 Q4 | 3.97 Million SEK | -8.37% |
| 2022 Q2 | 5.1 Million SEK | -12.88% |
| 2021 Q3 | 7.33 Million SEK | -9.0% |
| 2021 FY | 6.6 Million SEK | 125.49% |
| 2021 Q1 | 8.78 Million SEK | 200.0% |
| 2021 Q4 | 6.6 Million SEK | -10.04% |
| 2021 Q2 | 8.06 Million SEK | -8.18% |
| 2020 Q2 | 3.6 Million SEK | -12.98% |
| 2020 FY | 2.92 Million SEK | -35.57% |
| 2020 Q4 | 2.92 Million SEK | 20.8% |
| 2020 Q3 | 2.42 Million SEK | -32.81% |
| 2020 Q1 | 4.14 Million SEK | -8.78% |
| 2019 FY | 4.54 Million SEK | 0.0% |
| 2019 Q2 | - SEK | -100.0% |
| 2019 Q4 | 4.54 Million SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q1 | 5.71 Million SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2017 FY | - SEK | -100.0% |
| 2017 Q1 | 400 Thousand SEK | 0.0% |
| 2017 Q2 | - SEK | -100.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 FY | 400 Thousand SEK | 0.0% |
| 2016 Q4 | 400 Thousand SEK | 0.0% |
| 2015 FY | 400 Thousand SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 16.09 Million SEK | -71.249% |
| Ziccum AB (publ) | 857 Thousand SEK | -3116.569% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 4.97 Million SEK | -453.645% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 24.48 Million SEK | -12.569% |
| Genovis AB (publ.) | 79.32 Million SEK | 65.247% |
| Intervacc AB (publ) | 181 Thousand SEK | -15129.834% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.61 Million SEK | -33.744% |
| Active Biotech AB (publ) | 3 Million SEK | -818.867% |
| Magle Chemoswed Holding AB (publ) | 60.3 Million SEK | 54.287% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | 5 Million SEK | -451.32% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 71.4 Million SEK | 61.397% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Biovica International AB (publ) | 7.82 Million SEK | -252.146% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -6401.415% |
| Egetis Therapeutics AB (publ) | 108.6 Million SEK | 74.617% |
| Karolinska Development AB (publ) | 3.07 Million SEK | -797.915% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Amniotics AB (publ) | 2.58 Million SEK | -968.45% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -2656.6% |
| Calliditas Therapeutics AB (publ) | 979.13 Million SEK | 97.185% |
| Camurus AB (publ) | 24.5 Million SEK | -12.482% |
| Corline Biomedical AB | - SEK | -Infinity% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Hansa Biopharma AB (publ) | 866.76 Million SEK | 96.82% |
| Cyxone AB (publ) | 858 Thousand SEK | -3112.821% |
| ExpreS2ion Biotech Holding AB (publ) | 1.71 Million SEK | -1511.105% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 36.8 Million SEK | 25.109% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| Nanologica AB (publ) | 666 Thousand SEK | -4039.039% |
| SynAct Pharma AB | 637 Thousand SEK | -4227.473% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -3143.059% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 1.76 Million SEK | -1465.361% |
| BioInvent International AB (publ) | 23.24 Million SEK | -18.594% |
| Alzinova AB (publ) | 800 Thousand SEK | -3345.75% |
| Oncopeptides AB (publ) | 106.48 Million SEK | 74.113% |
| Pila Pharma AB (publ) | 773.08 Thousand SEK | -3465.737% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Simris Alg AB (publ) | 90.74 Million SEK | 69.621% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | 10.126% |
| Xbrane Biopharma AB (publ) | 231.47 Million SEK | 88.091% |
| Ascelia Pharma AB (publ) | 1.06 Million SEK | -2498.115% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |